Skip header and navigation

4 records – page 1 of 1.

Readability of New Aviation Chart Symbology in Day and NVG Reading Conditions.

https://arctichealth.org/en/permalink/ahliterature287611
Source
Aerosp Med Hum Perform. 2017 Nov 01;88(11):978-984
Publication Type
Article
Date
Nov-01-2017
Author
Anthony S Wagstaff
Terje Larsen
Source
Aerosp Med Hum Perform. 2017 Nov 01;88(11):978-984
Date
Nov-01-2017
Language
English
Publication Type
Article
Keywords
Aviation
Humans
Military Personnel
Night Vision
Reading
Sweden
Symbolism
Abstract
The Swedish Air Force (SwAF) conducted a study in 2010 to harmonize portrayal of aeronautical info (AI) on SwAF charts with NATO standards. A mismatch was found concerning vertical obstructions (VO). Norway regarded Sweden's existing symbology as a way to solve the problem of overcrowded air charts and the two countries started to cooperate. The result of this development was a new set of symbology for obstacles. The aim of this study was to test the readability of the new obstacle and power line symbols compared to the old symbols. We also wished to assess the readability in NVG illumination conditions, particularly regarding the new symbols compared to the old.
In a randomized controlled study design, 21 volunteer military pilots from the Norwegian and Swedish Air Force were asked to perform tracking and chart-reading tests. The chart-reading test scored both errors and readability using a predefined score index. Subjective scoring was also done at the end of the test day.
Overall response time improved by approximately 20% using the new symbology and error rate decreased by approximately 30-90% where statistically significant differences were found.
The tracking test turned out to be too difficult due to several factors in the experimental design. Even though some caution should be shown in drawing conclusions from this study, the general trends seem well supported with the number of aircrew subjects we were able to recruit.Wagstaff AS, Larsen T. Readability of new aviation chart symbology in day and NVG reading conditions. Aerosp Med Hum Perform. 2017; 88(11):978-984.
PubMed ID
29046172 View in PubMed
Less detail

Two Isomeric C16 Oxo-Fatty Acids from the Diatom Chaetoceros karianus Show Dual Agonist Activity towards Human Peroxisome Proliferator-Activated Receptors (PPARs) a/?.

https://arctichealth.org/en/permalink/ahliterature290687
Source
Mar Drugs. 2017 May 25; 15(6):
Publication Type
Journal Article
Date
May-25-2017
Author
Angel Moldes-Anaya
Thomas Sæther
Silvio Uhlig
Hilde I Nebb
Terje Larsen
Hans C Eilertsen
Steinar M Paulsen
Author Affiliation
Cardiovascular Research Group, Department of Medical Biology, UiT The Arctic University of Norway, 9019 Tromsø, Norway. angel.moldes-anaya@uit.no.
Source
Mar Drugs. 2017 May 25; 15(6):
Date
May-25-2017
Language
English
Publication Type
Journal Article
Keywords
Animals
COS Cells
Cell Line
Cercopithecus aethiops
Diatoms - chemistry
Fatty Acids - chemistry - pharmacology
Humans
Isomerism
Ligands
Metabolome - drug effects
Microalgae - chemistry
PPAR alpha - agonists - metabolism
PPAR gamma - agonists - metabolism
Abstract
The peroxisome proliferator-activated receptors (PPARs) function as ligand-activated transcription factors that convert signals in the form of lipids to physiological responses through the activation of metabolic target genes. Due to their key roles in lipid and carbohydrate metabolism, the PPARs are important drug targets. However, for several of the PPAR drugs currently in use, adverse side effects have been reported. In an effort to identify compounds from marine organisms that may serve as molecular scaffolds for the development of novel and safer PPAR-targeting drugs, we performed a bioassay-guided screening of organic extracts made from organisms supplied by the Norwegian Biobank of Arctic Marine Organisms (Marbank). Among several interesting hits, we identified two poorly described isomeric oxo-fatty acids from the microalgae Chaetoceros karianus for which we provide the first evidence that they might display dual specificity towards human PPARa and PPAR?. Principal component analysis showed that C. karianus stood out from other Chaetoceros species, both with respect to the metabolic profile and the PPAR activity. The isolation of these compounds holds the potential of uncovering a PPAR pharmacophore with tunable activity and specificity.
Notes
Cites: J Lipid Res. 2010 Jul;51(7):1886-96 PMID 20219900
Cites: Cell Mol Life Sci. 2004 Feb;61(4):393-416 PMID 14999402
Cites: Science. 1993 Jan 1;259(5091):87-91 PMID 7678183
Cites: Diabetologia. 2006 Sep;49(9):2162-73 PMID 16865359
Cites: Org Biomol Chem. 2005 Nov 21;3(22):4065-70 PMID 16267584
Cites: J Org Chem. 1997 Oct 17;62(21):7512-7515 PMID 11671879
Cites: Trends Endocrinol Metab. 2011 Jun;22(6):197-203 PMID 21632259
Cites: Nature. 2011 Sep 04;477(7365):477-81 PMID 21892191
Cites: Cell. 1994 Dec 30;79(7):1147-56 PMID 8001151
Cites: Diabetes. 2004 Feb;53 Suppl 1:S43-50 PMID 14749265
Cites: J Mol Biol. 2005 Dec 9;354(4):751-9 PMID 16271724
Cites: FASEB J. 2011 Aug;25(8):2538-50 PMID 21507897
Cites: Mar Drugs. 2013 Oct 30;11(11):4232-45 PMID 24177671
Cites: Biochem J. 2003 Feb 1;369(Pt 3):721-9 PMID 12408750
Cites: Cell. 2014 Oct 9;159(2):318-32 PMID 25303528
Cites: Expert Opin Ther Targets. 2017 Mar;21(3):333-348 PMID 28092722
Cites: J Appl Phycol. 2016;28:939-950 PMID 27057087
Cites: Nature. 2001 Jan 18;409(6818):307-12 PMID 11201732
Cites: Nature. 1998 Sep 10;395(6698):137-43 PMID 9744270
Cites: Nat Struct Mol Biol. 2008 Sep;15(9):924-31 PMID 19172745
Cites: Phytochem Rev. 2013;12:567-578 PMID 24078803
Cites: J Biol Chem. 2012 Aug 10;287(33):28169-79 PMID 22584573
Cites: Nat Rev Drug Discov. 2010 Sep;9(9):668-9 PMID 20811368
Cites: J Nat Prod. 2008 Feb;71(2):232-40 PMID 18220352
Cites: Endocrinology. 1994 Aug;135(2):798-800 PMID 8033830
Cites: Diabetes. 1997 Aug;46(8):1319-27 PMID 9231657
Cites: J Biol Chem. 1995 Jun 2;270(22):12953-6 PMID 7768881
Cites: Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4318-23 PMID 9113987
Cites: N Engl J Med. 2007 Jun 14;356(24):2457-71 PMID 17517853
Cites: J Biol Chem. 1995 Aug 18;270(33):19269-76 PMID 7642600
Cites: Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15712-7 PMID 14660788
Cites: Clin Sci (Lond). 2016 Sep 1;130(18):1603-14 PMID 27503945
Cites: Pharmacol Res Perspect. 2015 Jun;3(3):e00136 PMID 26171220
Cites: Curr Opin Pharmacol. 2006 Dec;6(6):606-14 PMID 16973418
Cites: Diabetes. 2004 May;53(5):1243-52 PMID 15111493
PubMed ID
28587091 View in PubMed
Less detail

Two Isomeric C16 Oxo-Fatty Acids from the Diatom Chaetoceros karianus Show Dual Agonist Activity towards Human Peroxisome Proliferator-Activated Receptors (PPARs) a/?.

https://arctichealth.org/en/permalink/ahliterature283135
Source
Mar Drugs. 2017 May 25;15(6)
Publication Type
Article
Date
May-25-2017
Author
Angel Moldes-Anaya
Thomas Sæther
Silvio Uhlig
Hilde I Nebb
Terje Larsen
Hans C Eilertsen
Steinar M Paulsen
Source
Mar Drugs. 2017 May 25;15(6)
Date
May-25-2017
Language
English
Publication Type
Article
Abstract
The peroxisome proliferator-activated receptors (PPARs) function as ligand-activated transcription factors that convert signals in the form of lipids to physiological responses through the activation of metabolic target genes. Due to their key roles in lipid and carbohydrate metabolism, the PPARs are important drug targets. However, for several of the PPAR drugs currently in use, adverse side effects have been reported. In an effort to identify compounds from marine organisms that may serve as molecular scaffolds for the development of novel and safer PPAR-targeting drugs, we performed a bioassay-guided screening of organic extracts made from organisms supplied by the Norwegian Biobank of Arctic Marine Organisms (Marbank). Among several interesting hits, we identified two poorly described isomeric oxo-fatty acids from the microalgae Chaetoceros karianus for which we provide the first evidence that they might display dual specificity towards human PPARa and PPAR?. Principal component analysis showed that C. karianus stood out from other Chaetoceros species, both with respect to the metabolic profile and the PPAR activity. The isolation of these compounds holds the potential of uncovering a PPAR pharmacophore with tunable activity and specificity.
PubMed ID
28587091 View in PubMed
Less detail